FK506 ( DrugBank: - )


1 disease
IDDisease name (Link within this page)Number of trials
222Primary nephrotic syndrome5

222. Primary nephrotic syndrome


Clinical trials : 285 Drugs : 285 - (DrugBank : 108) / Drug target genes : 62 - Drug target pathways : 191
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1ChiCTR-INR-15007440
2012-01-012015-10-30Multitarget Therapy for Treatment of Refractory idiopathic membranous nephropathyMultitarget Therapy for Treatment of Refractory idiopathic membranous nephropathy idiopathic membranous nephropathy1:Pred 1mg/kg+MMF 0.5Q12h+FK506 2mg Q12h ;2:Pred 1mg/kg+FK506 2mg Q12h;3:Pred 1mg/kg+CTX50mg BID;The first affiliated hospital of Zhengzhou UniversityNULLRecruiting1865Both1:50;2:50;3:50;China
2NCT01451489
(ClinicalTrials.gov)
October 13, 20115/8/2011The Efficacy and Safety of Tacrolimus in Treated Refractory Focal Segmental GlomerulosclerosisA Randomized,Multicentre,Prospective Study on the Tacrolimus(FK506)for Focal Segmental GlomerulosclerosisFSGSDrug: FK506;Drug: CyclophosphamideNanjing University School of MedicineNULLTerminated14 Years65 YearsAll70N/AChina
3NCT01161459
(ClinicalTrials.gov)
June 201012/7/2010Treatment of Idiopathic Membranous Nephropathy With Tripterygium Wilfordii Plus Steroid vs Tacrolimus Plus SteroidResearch Institute of Nephrology, Jinling HospitalIdiopathic Membranous NephropathyDrug: Tripterygium wilfordii;Drug: FK506Zhi-Hong Liu, M.D.NULLCompleted18 Years65 YearsBoth100N/AChina
4NCT00956059
(ClinicalTrials.gov)
September 200910/8/2009Therapeutic Effect of Low-dose Prednisone Combined With MMF and FK506 in Focal Segmental GlomerulosclerosisTherapeutic Effect of Low-dose Prednisone Combined With MMF and FK506 in Focal Segmental GlomerulosclerosisFocal Segmental GlomerulosclerosisDrug: prednisone, FK506, MMF;Drug: prednisoneXi’an Jiaotong University College of MedicineNULLNot yet recruiting16 Years70 YearsBoth40N/AChina
5ChiCTR-TRC-10001024
2008-01-012010-09-14Tacrolimus versus Cyclophosphamide for Therapy in steroid-resistant and steroid-dependent primary focal segmental glomerulosclerosisTacrolimus versus Cyclophosphamide for Therapy in steroid-resistant and steroid-dependent primary focal segmental glomerulosclerosis primary focal segmental glomerulosclerosisgroup A:intravenous CTX 0.5-0.75g/m2 Monthly+Oral prednisone (Prednisolone) 0.8mg/kg.d ;group B:Oral FK506 FK506 0.1mg/kg.d+prednisone (Prednisolone) 0.5mg/kg.d ;Shanghai Jiaotong University Affiliated Ruijin HospitalNULLCompleted1875Bothgroup A:30;group B:30;China